NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
AnPac Bio (NASDAQ: ANPC) today issued a correction to its press release dated Nov. 9, 2021, regarding the pricing of its underwritten public offering of American Depositary Shares (“ADSs”). According to the update, the original release referenced the dollar size of the offering and the number of ADSs being sold to include the exercise of the over-allotment option rather than just the base offering. The expected closing date has been updated to Nov. 15, 2021, for the offering of 1,132,111 ADSs, each at a public offering price of $2.22, for approximately $2.5 million in gross proceeds to the company. In connection with the offering, the company granted to the underwriter the option to purchase up to an additional 169,817 shares at the public offering price with the option exercisable within 45 days of the closing of the offering. EF Hutton, division of Benchmark Investments LLC, is acting as the sole book-running manager for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer